PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCTS • Segmentation by product • Comparison by product • Systems • Consumables • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY END-USER • Segmentation by end-user • Pharmaceutical and biotechnology companies • CROs • Academic research institutes • Cell banks • Others PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Mycoplasma testing market in Americas • Mycoplasma testing market in EMEA • Mycoplasma testing market in APAC • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers PART 13: MARKET TRENDS • Growing M&A and partnerships between CROs, and pharmaceutical and biotechnology companies • Technological advances PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Agilent Technologies • F. Hoffmann-La Roche • InvivoGen • Lonza • Merck • Thermo Fisher Scientific PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global microbiology testing market segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global mycoplasma testing market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global mycoplasma testing market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Global mycoplasma testing market by product – Market share 2017-2022 (%) Exhibit 19: Global mycoplasma testing market – Comparison by product Exhibit 20: Global mycoplasma testing systems market – Market size and forecast 2017-2022 ($ mn) Exhibit 21: Global mycoplasma testing systems market – Year-over-year growth 2018-2022 (%) Exhibit 22: Global mycoplasma testing consumables market – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Global mycoplasma testing consumables market – Year-over-year growth 2018-2022 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Global mycoplasma testing market by end-user – Market share 2017 (%) Exhibit 27: Global mycoplasma testing market by geography 2017-2022 (%) Exhibit 28: Regional comparison Exhibit 29: Mycoplasma testing market in Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 30: Mycoplasma testing market in Americas – Year-over-year growth 2018-2022 (%) Exhibit 31: Top 2 countries in Americas Exhibit 32: Mycoplasma testing market in EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 33: Mycoplasma testing market in EMEA – Year-over-year growth 2018-2022 (%) Exhibit 34: Top 2 countries in EMEA Exhibit 35: Mycoplasma testing market in APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 36: Mycoplasma testing market in APAC – Year-over-year growth 2018-2022 (%) Exhibit 37: Top 2 countries in APAC Exhibit 38: Market opportunity Exhibit 39: Collaborations between CROs and pharmaceutical companies Exhibit 40: M&A of vendors in mycoplasma testing market Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: Agilent Technologies: Overview Exhibit 47: Agilent Technologies: Business segments Exhibit 48: Agilent Technologies: Organizational developments Exhibit 49: Agilent Technologies: Geographic focus Exhibit 50: Agilent Technologies: Segment focus Exhibit 51: Agilent Technologies: Key offerings Exhibit 52: Agilent Technologies: Key customers Exhibit 53: F. Hoffmann-La Roche: Overview Exhibit 54: F. Hoffmann-La Roche: Business segments Exhibit 55: F. Hoffmann-La Roche: Organizational developments Exhibit 56: F. Hoffmann-La Roche: Geographic focus Exhibit 57: F. Hoffmann-La Roche: Segment focus Exhibit 58: F. Hoffmann-La Roche: Key offerings Exhibit 59: F. Hoffmann-La Roche: Key customers Exhibit 60: InvivoGen: Overview Exhibit 61: InvivoGen: Business segments Exhibit 62: InvivoGen: Organizational developments Exhibit 63: InvivoGen: Geographic focus Exhibit 64: InvivoGen: Segment focus Exhibit 65: InvivoGen: Key offerings Exhibit 66: InvivoGen: Key customers Exhibit 67: Lonza: Overview Exhibit 68: Lonza: Business segments Exhibit 69: Lonza: Organizational developments Exhibit 70: Lonza: Geographic focus Exhibit 71: Lonza: Segment focus Exhibit 72: Lonza: Key offerings Exhibit 73: Lonza: Key customers Exhibit 74: Merck: Overview Exhibit 75: Merck: Business segments Exhibit 76: Merck: Organizational developments Exhibit 77: Merck: Geographic focus Exhibit 78: Merck: Segment focus Exhibit 79: Merck: Key offerings Exhibit 80: Merck: Key customers Exhibit 81: Thermo Fisher Scientific: Overview Exhibit 82: Thermo Fisher Scientific: Business segments Exhibit 83: Thermo Fisher Scientific: Organizational developments Exhibit 84: Thermo Fisher Scientific: Geographic focus Exhibit 85: Thermo Fisher Scientific: Segment focus Exhibit 86: Thermo Fisher Scientific: Key offerings Exhibit 87: Thermo Fisher Scientific: Key customers

Agilent Technologies F. Hoffmann-La Roche InvivoGen Lonza Merck Thermo Fisher Scientific